Several Key Catalysts Lay Ahead For Gilead Sciences In The Next Year
November 14, 2016 at 16:00 PM EST
Stifel Nicolaus has started coverage on Gilead Sciences, Inc. (NASDAQ: GILD) with a Buy rating and $100 target price on improving HCV ...